Overall population | Group 1 | Group 2 | p value | |
---|---|---|---|---|
Number of patients | 119 | 71 | 48 | |
Median age, years (IQR) | 66 (48–76) | 64 (48–76) | 69 (53–76) | < 0.05 |
Median BMI, kg/m2 (IQR) | 23.5 (18.0–30.6) | 23.6 (18.1–28.9) | 22.9 (18.0–30.6) | 0.8 |
Median PSA, ng/mL (IQR) | 7.8 (3.2–37.1) | 7.8 (3.2–34.6) | 7.7 (4.3–37.1) | 0.45 |
Clinical stage | ||||
< T2c | 108 | 64 | 44 | 0.96 |
T3a | 10 | 6 | 4 | |
T3b | 1 | 1 | 0 | |
T4 | 0 | 0 | 0 | |
GS of biopsy | ||||
< 6 | 21 | 13 | 8 | 0.46 |
7 | 50 | 25 | 25 | |
> 8 | 48 | 33 | 15 | |
Risk class (NCCN) | ||||
Low | 14 | 9 | 5 | 0.54 |
Intermediate | 53 | 27 | 26 | |
High | 52 | 35 | 17 | |
Lymph node dissection (%) | 105 (88.2) | 62 (87.3) | 43 (89.6) | 0.75 |
Nerve sparing (%) | 51 (42.8) | 28 (39.4) | 23 (47.9) | 0.15 |
Median PV, mL (IQR) | 26.0 (9.6–66.1) | 24.8 (11.1–53.2) | 32.8 (9.6–66.1) | < 0.01 |
Median MUL, mm (IQR) | 12.1 (8.9–16.1) | 12.1 (9.1–15.3) | 12.9 (8.9–16.1) | 0.53 |
Median MUW, mm (IQR) | 10.6 (9.8–13.5) | 10.8 (9.9–13.4) | 10.3 (9.8–13.5) | 0.76 |
Median LT, mm (IQR) | 11.1 (7.9–15.1) | 11.0 (8.3–15.1) | 11.3 (7.9–15.1) | 0.66 |
Median IPP, mm (IQR) | 3.8 (0.0–16.5) | 1.0 (0.0–4.9) | 7.8 (6.2–16.5) | < 0.01 |
Median IPSS Total score (IQR) | 6 (0–28) | 6 (0–22) | 8 (0–28) | < 0.05 |
Median IPSS voiding symptom score (IQR) | 4 (0–18) | 3 (0–15) | 5 (0–18) | < 0.01 |
Median IPSS storage symptom score (IQR) | 4 (0–12) | 3 (0–12) | 4 (0–12) | 0.55 |
Median OABSS score (IQR) | 3 (0–10) | 2 (0–10) | 4 (2–10) | 0.45 |
Median QOL index (IQR) | 3 (0–6) | 3 (0–6) | 3 (0–6) | 0.35 |
Median compliance, mL/cmH2O (IQR) | 49.8 (5.0–290.2) | 55.9 (5.0–290.2) | 42.4 (5.4–153.9) | < 0.01 |
Median FDV, mL (IQR) | 144 (47–400) | 144 (81–400) | 134 (47–301) | 0.62 |
Median MCC, mL (IQR) | 277 (55–470) | 282 (120–470) | 264 (55–431) | 0.96 |
Median PdetQmax, cmH2O (IQR) | 45 (6–90) | 41 (6–89) | 48 (28–90) | < 0.01 |
DO (%) | 10 (8.4) | 7 (9.8) | 3 (6.2) | 0.22 |